SCHEMBL3972857

SCHEMBL3972857

Clc1ccc2nc(-c3ccc(Br)cc3)nc(Cl)c2c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.50
RAB9A P51151 2/20 0.50
MAPK1 P28482 1/20 0.50
HTT P42858 1/20 0.50
ADORA3 P0DMS8 1/20 0.47
CYP1B1 Q16678 2/20 0.45
CYP1A1 P04798 1/20 0.45
CYP1A2 P05177 1/20 0.45
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
DHODH Q02127 1/20 0.42
AHR P35869 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
RXFP1 Q9HBX9 1/20 0.41
PTGES O14684 1/20 0.40
ALDH1A1 P00352 1/20 0.40
ALOX5 P09917 1/20 0.40
CYP2C9 P11712 1/20 0.40
HPGD P15428 1/20 0.40
CASP7 P55210 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3973373 0.87 CYP1A1 (0.42) NPC1RAB9AMAPK1HTTADORA3
SCHEMBL3575071 0.85 MAPK1 (0.67) NPC1RAB9AMAPK1HTTMEN1
SCHEMBL8268904 0.84 DHODH (0.43) CYP1B1CYP1A1CYP1A2DHODHAHR
SCHEMBL3973898 0.84 LMNA (0.45) NPC1RAB9AHTTADORA3CYP1B1
SCHEMBL3497699 0.82 HTT (0.49) NPC1RAB9AMAPK1HTTADORA3
SCHEMBL3461641 0.82 MAPK1 (0.54) NPC1RAB9AMAPK1HTTMEN1
SCHEMBL5793174 0.80 CYP1B1 (0.64) NPC1RAB9AHTTCYP1B1CYP1A1
SCHEMBL3459657 0.79 HTT (0.49) NPC1RAB9AMAPK1HTTCYP1B1
SCHEMBL5309273 0.78 KDM1A (0.49) NPC1RAB9AMAPK1HTT
SCHEMBL2154965 0.76 NPC1 (0.46) NPC1RAB9AMAPK1HTTADORA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7547702-B2 4-amino-quinazolines ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) 2009-06-16 US disclosed
US-20060019974-A1 Glycoprotein antagonist; anticholesterol agents; cardiovascular disorders; strokes; antiischemic agents ORTHO-MCNEIL PHARMACEUTICALS, INC. 2006-01-26 US disclosed
WO-2004030672-A1 USE OF 4 AMINO-QUINAZOLINES AS ANTI CANCER AGENTS MERCK PATENT GMBH (DE) 2004-04-15 WO disclosed
EP-1318984-A1 4-AMINO-QUINAZOLINES MERCK PATENT GmbH (DE) 2003-06-18 EP disclosed
WO-2002024667-A1 4-AMINO-QUINAZOLINES MERCK PATENT GMBH (DE) 2002-03-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060019974-A1 Glycoprotein antagonist; anticholesterol agents; cardiovascular disorders; strokes; antiischemic agents SERPINA3, APOL1, MGAT3 NPC1 151/4885RAB9A 2468/4885MAPK1 3502/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.